EQUITY RESEARCH MEMO
Prolifagen Therapeutics
Generated 5/10/2026
Executive Summary
Conviction (model self-assessment)60/100
Prolifagen Therapeutics is a preclinical-stage biotechnology company developing microRNA-based therapies to regenerate damaged heart muscle after a myocardial infarction. Heart failure remains a leading cause of morbidity and mortality worldwide, with limited options to restore lost cardiomyocytes. Prolifagen's platform leverages specific microRNAs to induce proliferation of existing cardiomyocytes, aiming to reverse cardiac dysfunction and reduce the economic burden of heart failure. The company is based in San Diego and was founded in 2018.
Upcoming Catalysts (preview)
- TBDCompletion of large animal efficacy study70% success
- TBDSeries A financing round50% success
- TBDIND-enabling toxicology study results40% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)